Reed F Beall
Biographic Data
| ID | 2254767 |
|---|---|
| NAME | Reed F Beall |
| GIVEN NAMES | Reed F |
| FAMILY NAME | Beall |
| SIGNATURE | BEALL R F |
| AFFILIATIONS | University of Calgary |
| ORCID | 0000-0001-8188-7616 |
| VERIFIED | Yes |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 5 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2017 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
An environmental scan of financial incentives to increase access to healthy foods
Considerable heterogeneity was observed in incentive structures, values, and frequencies. Justifications for these designs were often lacking, highlighting the need for further research that directly compares the impact of different incentive structures, amounts, and frequencies on food purchases. Until more empirical evidence is available, program design choices can be guided by precedent, modeled after policy options under consideration (e.g., …
Exploring the prospective acceptability of a healthy food incentive program from the perspective of people with type 2 diabetes and experiences of household food insecurity in Alberta, Canada
Objective: FoodRx is a 12-month healthy food prescription incentive program for people with type 2 diabetes (T2DM) and experiences of household food insecurity. In this study, we aimed to explore potential users’ prospective acceptability (acceptability prior to program use) of the design and delivery of the FoodRx incentive and identify factors influencing prospective acceptability. Design: We used a qualitative descriptive approach and purposiv…
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
In 2015, the World Health Organization (WHO) Expert Committee approved the addition of 16 cancer medicines to the WHO Model List of Essential Medicines (EML), bringing the total number of cancer medicines on the list to 46. This change represented the first major revision to the EML oncology section in recent history and reinforces international recognition of the need to ensure access and affordability for cancer treatments. Importantly, many lo…
In which developing countries are patents on essential medicines being filed
BACKGROUND: This article is based upon data gathered during a study conducted in partnership with the World Intellectual Property Organization on the patent status of products appearing on the World Health Organization's 2013 Model List of Essential Medicines (MLEM). It is a statistical analysis aimed at answering: in which developing countries are patents on essential medicines being filed? METHODS: Patent data were collected by linking those li…
A method for understanding generic procurement of HIV medicines by developing countries with patent protection
No prominent works on this page.
In which developing countries are patents on essential medicines being filed
BACKGROUND: This article is based upon data gathered during a study conducted in partnership with the World Intellectual Property Organization on the patent status of products appearing on the World Health Organization's 2013 Model List of Essential Medicines (MLEM). It is a statistical analysis aimed at answering: in which developing countries are patents on essential medicines being filed? METHODS: Patent data were collected by linking those li…
A method for understanding generic procurement of HIV medicines by developing countries with patent protection
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
In 2015, the World Health Organization (WHO) Expert Committee approved the addition of 16 cancer medicines to the WHO Model List of Essential Medicines (EML), bringing the total number of cancer medicines on the list to 46. This change represented the first major revision to the EML oncology section in recent history and reinforces international recognition of the need to ensure access and affordability for cancer treatments. Importantly, many lo…
Exploring the prospective acceptability of a healthy food incentive program from the perspective of people with type 2 diabetes and experiences of household food insecurity in Alberta, Canada
Objective: FoodRx is a 12-month healthy food prescription incentive program for people with type 2 diabetes (T2DM) and experiences of household food insecurity. In this study, we aimed to explore potential users’ prospective acceptability (acceptability prior to program use) of the design and delivery of the FoodRx incentive and identify factors influencing prospective acceptability. Design: We used a qualitative descriptive approach and purposiv…
An environmental scan of financial incentives to increase access to healthy foods
Considerable heterogeneity was observed in incentive structures, values, and frequencies. Justifications for these designs were often lacking, highlighting the need for further research that directly compares the impact of different incentive structures, amounts, and frequencies on food purchases. Until more empirical evidence is available, program design choices can be guided by precedent, modeled after policy options under consideration (e.g., …
Business (4 works) · Economics (4 works) · Medicine (4 works) · Economic growth (3 works) · Essential medicines (3 works) · Intellectual property (3 works) · Law (3 works) · Pharmaceutical Economics and Policy (3 works) · Political science (3 works) · Developing country (2 works)